← Back to news
Real-world outcomes after switching to faricimab in treatment-resistant diabetic macular edema: A 1-year observational study with choroidal thickness assessment
Published: June 10, 2026 · Plos.org
View original
Approximately 40% of diabetic macular edema (DME) cases are resistant to conventional anti-vascular endothelial growth factor (VEGF) therapy. Although faricimab (an antibody against VEGF-A and angiopoietin-2 [Ang-2]) has shown efficacy in treatment-naïve DME,…
